Valuation: Sensorion

Market Cap 108M 124M 102M 92.25M 173M 11.93B 174M 1.22B 468M 6.05B 467M 457M 19.3B P/E 2026 *
-27.9x
P/E 2027 * -5.23x
Enterprise Value -24.24M -27.98M -22.92M -20.75M -38.94M -2.68B -39.24M -274M -105M -1.36B -105M -103M -4.34B EV / Sales 2026 *
-0.94x
EV / Sales 2027 * 16.9x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1,103.22%
1 week-17.41%
Current month-22.17%
1 month-27.31%
3 months-16.92%
6 months-68.28%
Current year-37.88%
1 week 9.45
Extreme 9.45
12.25
1 month 9.45
Extreme 9.45
14.95
Current year 9.45
Extreme 9.45
40.4
1 year 9.45
Extreme 9.45
40.4
3 years 7.72
Extreme 7.72
52
5 years 7.72
Extreme 7.72
114.5
10 years 7.72
Extreme 7.72
387
Manager TitleAgeSince
Chief Executive Officer 59 2026-05-31
Director of Finance/CFO - 2024-06-25
Chief Tech/Sci/R&D Officer - 2023-12-10
Director TitleAgeSince
Director/Board Member - 2015-03-08
Director/Board Member 43 -
Chairman 61 2023-03-29
Date Insider Type Main position Quantity % Market Cap. Importance
2/6/26
Redmile Biopharma Investments III LP
BuyCompany 18,928,571 6.2956%
1/31/26
Sofinnova Partners SAS
BuyCompany 10,714,285 3.5636%
4/18/24
Redmile Biopharma Investments III LP
BuyCompany 2,781,914 1.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+1,103.22%-17.41%-30.68%-68.28% 124M
+0.56%-3.38%-1.83%+8.00% 45.81B
-0.12%-1.19%+343.42%+545.03% 43.91B
+1.51%+4.04%+45.01%+27.38% 44.39B
-2.07%-1.42%+4.28%+72.97% 39.4B
-0.73%-3.06%+9.63%+38.92% 31.26B
-9.49%-11.23% - - 15.75B
+4.21%+5.01%+24.99%+121.62% 17.32B
+1.83%+3.20%+16.49%+32.73% 14.73B
-0.08%-2.81%+79.24%+31.27% 13.03B
Average +109.88%+92.15%+54.51%+89.96% 26.57B
Weighted average by Cap. +0.26%-0.79%+76.68%+130.39%

Financials

2026 *2027 *
Net sales 25.87M 29.87M 24.46M 22.15M 41.57M 2.86B 41.88M 292M 112M 1.45B 112M 110M 4.63B 6.4M 7.38M 6.05M 5.47M 10.27M 708M 10.35M 72.16M 27.76M 359M 27.73M 27.12M 1.15B
Net income 15.8M 18.24M 14.94M 13.53M 25.39M 1.75B 25.58M 178M 68.59M 887M 68.52M 67M 2.83B -36.12M -41.7M -34.16M -30.92M -58.03M -4B -58.47M -408M -157M -2.03B -157M -153M -6.47B
Net Debt -132M -152M -125M -113M -212M -14.62B -214M -1.49B -573M -7.41B -572M -560M -23.64B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change Volume
26-09-15 €10.47 -3.74% 9,802
26-09-14 €10.88 -4.61% 27,936
26-09-11 €11.40 -1.94% 14,652
26-09-10 €11.63 -2.52% 8,679
26-09-09 €11.93 -5.92% 11,216
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.47EUR
Average target price
56.88EUR
Spread / Average Target
+443.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALSEN Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!